Clopixol-acufaz, 50 mg/ml oil 1 ml 5 pcs

Pharmgroup:

Antipsychotic (neuroleptic).

Pharmic action:

Antipsychotic (neuroleptic), a thioxanthene derivative. Clopixol has pronounced antipsychotic and specific inhibitory effects.

Clopixol may also have a transient, dose-dependent sedative effect, the rapid development of which at the beginning of therapy (before the onset of antipsychotic action) is an advantage in the treatment of acute and subacute psychosis. Tolerance to the nonspecific sedative effect of the drug occurs quickly.

The drug is especially indicated for agitation, anxiety, hostility, or aggressiveness because of its specific inhibitory effect.

A single injection of Clopixol-Acufase provides a pronounced and rapid relief of psychotic symptoms. The duration of the antipsychotic effect of the drug after one injection is 2-3 days.

The nonspecific sedative effect is seen after 2 h, reaches a maximum after about 8 h, after that it is significantly reduced and is weak with repeated injections.

The therapeutic effect of Clopixol depot is significantly more prolonged compared to Clopixol. This allows for confidence in continuous antipsychotic treatment with Clopixol Depot, which is especially important for patients who do not follow physician’s orders.

Clopixol depot prevents the development of frequent relapses associated with patients arbitrarily interrupting oral medications.

Indications

Acute and chronic schizophrenia and other psychotic disorders, especially with hallucinations, paranoid delusions and thought disorders; states of agitation, increased anxiety, hostility, aggressiveness.

Pharmacological effect

Pharmaceutical group:

antipsychotic (neuroleptic).

Pharmaceutical action:

Antipsychotic drug (neuroleptic), thioxanthene derivative. Clopixol has a pronounced antipsychotic and specific inhibitory effect.

Clopixol may also have a transient, dose-dependent sedative effect, the rapid development of which at the beginning of therapy (before the onset of antipsychotic action) is an advantage in the treatment of acute and subacute psychoses. Tolerance to the nonspecific sedative effect of the drug occurs quickly.

Due to its specific inhibitory effect, the drug is especially indicated for agitation, restlessness, hostility or aggressiveness.

A single injection of Clopixol-acuphas provides significant and rapid relief of psychotic symptoms. The duration of the antipsychotic effect of the drug after one injection is 2-3 days.

The nonspecific sedative effect appears after 2 hours, reaches a maximum after about 8 hours, after which it decreases significantly and is weakly manifested with repeated injections.

The therapeutic effect of Clopixol depot is significantly more prolonged compared to Clopixol. This allows confident continuous antipsychotic treatment with Clopixol depot, which is especially important for patients who do not comply with medical prescriptions.

Clopixol depot prevents the development of frequent relapses associated with arbitrary interruption of patients taking oral medications.

Special instructions

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication of antipsychotic drug use.

The main characteristics of NMS are hyperthermia, muscle rigidity and impaired consciousness in combination with dysfunction of the autonomic nervous system (labile blood pressure, tachycardia, increased sweating).

In addition to immediate cessation of antipsychotic medication, the use of general supportive measures and symptomatic treatment is essential.

Active ingredient

Zuclopenthixol

Composition

1 ml:

– zuclopenthixol acetate 50 mg

Excipients:

triglycerides.

Pregnancy

Contraindicated. Nursing mothers should stop breastfeeding.

Contraindications

Chronic hepatitis; severe cardiovascular diseases.

Side Effects

Possible extrapyramidal disorders, tardive dyskinesia, neuroleptic malignant syndrome, drowsiness, dizziness, dry mouth, impaired accommodation, urinary retention, constipation, tachycardia, orthostatic hypotension, changes in liver function tests.

Interaction

Strengthens the sedative effect of alcohol, barbiturates and other central nervous system depressants, reduces the sedative effect of levodopa and other adrenergic drugs.

Weakens the hypotensive effect of guanethidine and its analogues.

The risk of developing extrapyramidal disorders is increased by metoclopramide and piperazine.

Overdose

Symptoms: drowsiness, hypo- or hyperthermia, hypotension, extrapyramidal symptoms, convulsions, shock, coma.

Treatment: symptomatic and supportive.

Measures should be taken to maintain the functioning of the respiratory and cardiovascular systems.

Epinephrine (adrenaline) should not be used because this may lead to a subsequent decrease in blood pressure.

Seizures can be treated with diazepam, and extrapyramidal symptoms with biperiden.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 30 °C

Shelf life

2 years

Manufacturer

H. Lundbeck A/O, Denmark